Published in Toxicol Pathol on January 26, 2009
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Current and Novel Inhibitors of HIV Protease. Viruses (2009) 1.10
Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem (2010) 0.94
Renal transplantation in patients with HIV. Nat Rev Nephrol (2009) 0.92
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc (2015) 0.91
Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res (2010) 0.91
Proliferative and non-proliferative lesions of the rat and mouse soft tissue, skeletal muscle and mesothelium. J Toxicol Pathol (2013) 0.90
GRP78 plays an essential role in adipogenesis and postnatal growth in mice. FASEB J (2012) 0.89
Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.86
HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One (2013) 0.86
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS. J Mol Cell Cardiol (2010) 0.85
Fiber type-specific differences in glucose uptake by single fibers from skeletal muscles of 9- and 25-month-old rats. J Gerontol A Biol Sci Med Sci (2012) 0.85
Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact (2015) 0.80
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons. Clin Infect Dis (2015) 0.77
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction. Free Radic Biol Med (2016) 0.75
Alcoholic Extract of Lotus Leaves Improves Lipid Profile in Rats with HIV Protease Inhibitor-induced Dyslipidaemia. West Indian Med J (2015) 0.75
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clin Trials (2016) 0.75
Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 33.06
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest (2002) 21.08
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67
Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell (2000) 13.44
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med (2001) 9.68
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab (2001) 9.53
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest (2005) 8.45
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Chemokines in the pathogenesis of vascular disease. Circ Res (2004) 4.64
Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr (2005) 4.02
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol (2002) 3.56
Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology (2003) 3.42
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 3.41
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr (2000) 3.11
Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem (2004) 2.87
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem (2000) 2.55
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 2.47
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 2.31
Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS (2002) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med (2001) 2.14
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS (1998) 2.05
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology (2003) 2.02
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS (2006) 1.92
Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 1.90
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis (2005) 1.89
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS (2001) 1.81
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 1.80
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS (2002) 1.79
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 1.73
Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism (1991) 1.68
Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry (2003) 1.67
Fat distribution and metabolic changes in patients with HIV infection. AIDS (1999) 1.67
Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS (1999) 1.66
Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res (2003) 1.65
The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS (2004) 1.64
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes (2001) 1.61
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (2000) 1.60
Metabolism of lipids in human white adipocyte. Diabetes Metab (2004) 1.56
Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes (2004) 1.56
Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem (2001) 1.55
The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab (1993) 1.53
HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem (2001) 1.53
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS (2007) 1.49
Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis (2005) 1.46
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis (2006) 1.42
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes (2005) 1.42
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr (2005) 1.42
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis (2003) 1.42
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS (2003) 1.40
Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes (2003) 1.35
A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem (2004) 1.35
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med (2003) 1.34
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol (2005) 1.32
Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J (1992) 1.32
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res (2002) 1.31
Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS (2003) 1.29
Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes (2002) 1.28
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother (2007) 1.27
Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med (2005) 1.26
Protease inhibitor-associated hyperglycaemia. Lancet (1997) 1.26
HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes (2003) 1.25
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab (2005) 1.21
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A (2007) 1.20
Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol Endocrinol (2003) 1.19
Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med (1991) 1.15
Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis (2006) 1.15
Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes (2006) 1.14
The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes (2001) 1.14
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr (2006) 1.12
Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism (2006) 1.10
How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem (1999) 1.07
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr (2005) 1.07
Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev (2007) 1.06
Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.05
Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol (2002) 1.03
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS (2004) 1.02
Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand (2005) 1.02
Anti-HIV drugs and the mitochondria. Biochim Biophys Acta (2006) 1.01
Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab (2005) 1.01
Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab (2004) 1.01
Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS (2002) 0.99
Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr (2005) 0.98
Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord (2005) 0.97
Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci (2005) 0.95
The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia (2000) 0.95
Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis (2003) 0.95
Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract (2007) 0.93
Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des (2007) 0.92
Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother (2006) 0.90
The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism. Curr Infect Dis Rep (2004) 0.90
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes Metab (2006) 0.89
Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Diabetes (2005) 0.88
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature (2007) 4.59
Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab (2005) 3.51
Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr (2002) 3.33
Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. Hepatology (2004) 2.62
Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation (2004) 2.35
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis (2007) 2.34
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS (2002) 2.17
Bacterial community structures are unique and resilient in full-scale bioenergy systems. Proc Natl Acad Sci U S A (2011) 2.05
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS (2006) 1.92
Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol (2007) 1.90
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis (2005) 1.89
Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes (2003) 1.88
Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass. Am J Physiol Endocrinol Metab (2002) 1.82
Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2007) 1.77
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 1.73
The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS (2004) 1.64
Liver regeneration is impaired in lipodystrophic fatty liver dystrophy mice. Hepatology (2010) 1.64
Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr (2007) 1.63
Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol (1985) (2004) 1.57
Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem (2005) 1.52
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem (2005) 1.49
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read (2005) 1.40
Delayed hepatocellular mitotic progression and impaired liver regeneration in early growth response-1-deficient mice. J Biol Chem (2004) 1.40
Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (2008) 1.38
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr (2007) 1.37
A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem (2004) 1.35
Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab (2003) 1.33
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol (2005) 1.32
Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism (2006) 1.29
HIV infection and the gastrointestinal tract. AIDS (2005) 1.26
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab (2007) 1.24
Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab (2002) 1.20
Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab (2003) 1.19
Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther (2007) 1.14
Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes (2011) 1.12
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med (2004) 1.10
Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass surgery (GBP). Obes Surg (2012) 1.07
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr (2005) 1.07
Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr (2002) 1.06
Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol (2013) 1.06
HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr (2004) 1.06
HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One (2011) 1.04
Multicomponent methods: evaluation of new and traditional soft tissue mineral models by in vivo neutron activation analysis. Am J Clin Nutr (2002) 1.03
Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr (2002) 1.01
Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci (2010) 1.01
Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis (2001) 1.01
Rosiglitazone inhibits mouse liver regeneration. FASEB J (2006) 1.00
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses (2004) 1.00
GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol (2012) 1.00
Total body protein: a new cellular level mass and distribution prediction model. Am J Clin Nutr (2003) 0.98
Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg (2002) 0.98
N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab (2009) 0.97
The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J Biomed Sci (2003) 0.97
Indinavir increases glucose production in healthy HIV-negative men. AIDS (2004) 0.96
Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. J Gerontol A Biol Sci Med Sci (2011) 0.96
Lymphogranuloma venereum in human immunodeficiency virus-infected individuals in New York City. J Clin Gastroenterol (2006) 0.95
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr (2007) 0.95
Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One (2011) 0.95
Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem (2010) 0.94
HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV/Microsporidia-infected jejunal mucosa. AIDS (2007) 0.94
Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 0.94
Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes (2009) 0.92
Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model. J Acquir Immune Defic Syndr (2006) 0.90
Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr (2006) 0.89
Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J Acquir Immune Defic Syndr (2006) 0.86
Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb (2011) 0.86
Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir. Arterioscler Thromb Vasc Biol (2009) 0.86
Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr (2008) 0.85
The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab (2011) 0.85
The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis (2004) 0.83
Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int (2014) 0.83
High-precision isotopic analysis of palmitoylcarnitine by liquid chromatography/electrospray ionization ion-trap tandem mass spectrometry. Rapid Commun Mass Spectrom (2006) 0.83
HIV enteropathy and aging: gastrointestinal immunity, mucosal epithelial barrier, and microbial translocation. Curr Opin HIV AIDS (2014) 0.82
Effect of HIV infection on body composition and fat distribution in Rwandan women. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.82
Gastric cancer in Zambian adults: a prospective case-control study that assessed dietary intake and antioxidant status by using urinary isoprostane excretion. Am J Clin Nutr (2013) 0.82
Lipodystrophy in HIV patients: its challenges and management approaches. HIV AIDS (Auckl) (2011) 0.81
Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2005) 0.81
A Case of Staphylococcus aureus Enterocolitis: A Rare Entity. Gastroenterol Hepatol (N Y) (2010) 0.81
Gastric carcinoids in a patient with pernicious anemia and familial adenomatous polyposis. J Clin Gastroenterol (2002) 0.80
Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antivir Ther (2008) 0.80
Gastric toxoplasmosis as the presentation of acquired immunodeficiency syndrome. Arch Pathol Lab Med (2005) 0.79
Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy. Cardiovasc Endocrinol (2012) 0.79
Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol (1985) (2003) 0.79
The role of Ile87 of CYP158A2 in oxidative coupling reaction. Arch Biochem Biophys (2011) 0.78
Staphylococcal enterocolitis: forgotten but not gone? Dig Dis Sci (2009) 0.78
Intermuscular adipose tissue and metabolic associations in HIV infection. Obesity (Silver Spring) (2010) 0.78
Effect of HIV infection on the prevalence of colorectal adenomas during screening colonoscopy. J Clin Gastroenterol (2010) 0.77
Use of a Durnin-Womersley formula to estimate change in subcutaneous fat content in HIV-infected subjects. Am J Clin Nutr (2002) 0.77
Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2013) 0.77
Teaching the competencies: using observed structured clinical examinations for faculty development. Am J Gastroenterol (2010) 0.77
HIV enteropathy: HAART reduces HIV-induced stem cell hyperproliferation and crypt hypertrophy to normal in jejunal mucosa. J Clin Pathol (2013) 0.76
Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2007) 0.76
A comparison of abdominal subcutaneous adipose tissue pattern in obese and lean HIV-infected women. J Nutr (2005) 0.76